Xencor Inc

NASDAQ:XNCR   11:11:35 AM EDT
35.43
-0.14 (-0.39%)
Products

Xencor Presents Updated Data From Phase 1 Study Of Vudalimab, PD-1 X CTLA-4 Bispecific Antibody

Published: 11/12/2021 12:25 GMT
Xencor Inc (XNCR) - Xencor Presents Updated Data From the Phase 1 Study of Vudalimab, Pd-1 X Ctla-4 Bispecific Antibody, at the Sitc Annual Meeting.
Xencor Inc - Vudalimab Was Generally Well-tolerated; Objective Responses Observed Across Multiple Tumor Types.
Xencor Inc - Additional Complete Response Observed in Patient With Advanced Brca1+ High-grade Serous Ovarian Cancer.